Heemal Hansraj Dhanjee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Heemal Hansraj Dhanjee has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Stephen L. Buchwald
Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
7 shared publications - Bradley Lether Pentelute
Department of Chemistry Massachusetts Institute of Technology Cambridge Massachusetts USA
6 shared publications - Jacob Rodriguez
Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
4 shared publications Ivan Buslov
Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
3 shared publications- Joseph S. Brown
Massachusetts Institute of Technology
3 shared publications Alexander R. Loftis
2 shared publications
Latest Publications
- 13 July 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (29) , 20080-20085
Site-Specific Antibody Prodrugs via S-Arylation: a Bioconjugation Approach Toward Masked Tyrosine Analogues
The utility of antibody therapeutics is hampered by potential cross-reactivity with healthy tissue. Over the past decade, significant advances have been made in the design of activatable antibodies, which increase, or create altogether, the therapeutic window of a parent antibody. Of these, antibody prodrugs (pro-antibodies) are masked antibodies that have advanced the most for therapeutic use. They are designed to reveal the active, parent antibody only when encountering proteases upregulated in the microenvironment of the targeted disease tissue, thereby minimizing off-target activity. However, current pro-antibody designs are relegated to fusion proteins that append masking groups restricted to the use of only canonical amino acids, offering excellent control of the site of introduction, but with no authority over where the masking group is installed other than the N-terminus of the antibody. Here, we present a palladium-based bioconjugation approach for the site-specific introduction of a masked tyrosine mimic in the complementary determining region of the FDA approved antibody therapeutic ipilimumab used as a model system. The approach enables the introduction of a protease cleavable group tethered to noncanonical polymers (polyethylene glycol (PEG)) resulting in 47-fold weaker binding to cells expressing CTLA-4, the target antigen of ipilimumab. Upon exposure to tumor-associated proteases, the masking group is cleaved, unveiling a tyrosine-mimic (dubbed hydroxyphenyl cysteine (HPC)) that restores (>90% restoration) binding affinity to its target antigen.
- 13 July 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (29) , 20080-20085
Site-Specific Antibody Prodrugs via S-Arylation: a Bioconjugation Approach Toward Masked Tyrosine Analogues
The utility of antibody therapeutics is hampered by potential cross-reactivity with healthy tissue. Over the past decade, significant advances have been made in the design of activatable antibodies, which increase, or create altogether, the therapeutic window of a parent antibody. Of these, antibody prodrugs (pro-antibodies) are masked antibodies that have advanced the most for therapeutic use. They are designed to reveal the active, parent antibody only when encountering proteases upregulated in the microenvironment of the targeted disease tissue, thereby minimizing off-target activity. However, current pro-antibody designs are relegated to fusion proteins that append masking groups restricted to the use of only canonical amino acids, offering excellent control of the site of introduction, but with no authority over where the masking group is installed other than the N-terminus of the antibody. Here, we present a palladium-based bioconjugation approach for the site-specific introduction of a masked tyrosine mimic in the complementary determining region of the FDA approved antibody therapeutic ipilimumab used as a model system. The approach enables the introduction of a protease cleavable group tethered to noncanonical polymers (polyethylene glycol (PEG)) resulting in 47-fold weaker binding to cells expressing CTLA-4, the target antigen of ipilimumab. Upon exposure to tumor-associated proteases, the masking group is cleaved, unveiling a tyrosine-mimic (dubbed hydroxyphenyl cysteine (HPC)) that restores (>90% restoration) binding affinity to its target antigen.
- 31 May 2022
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 144 (22) , 10096
Correction to “Palladium-Mediated Incorporation of Carboranes into Small Molecules, Peptides, and Proteins”
- 31 May 2022
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 144 (22) , 10096
Correction to “Palladium-Mediated Incorporation of Carboranes into Small Molecules, Peptides, and Proteins”
- 19 April 2022
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 144 (17) , 7852-7860
Palladium-Mediated Incorporation of Carboranes into Small Molecules, Peptides, and Proteins
Carboranes represent a class of compounds with increasing therapeutic potential. However, few general approaches to readily embed carboranes into small molecules, peptides, and proteins are available. We report a strategy based on palladium-mediated C–X (X = C, S, and N) bond formation for the installation of carborane-containing moieties onto small molecules and peptides. We demonstrate the ability of Pd-based reagents with appropriate ligands to overcome the high hydrophobicity of the carborane group and enable chemoselective conjugation of cysteine residues at room temperature in aqueous buffer. Accordingly, carboranes can be efficiently installed on proteins by employing a combination of a bis-sulfonated biarylphosphine-ligated Pd reagent in an aqueous histidine buffer. This method is successfully employed on nanobodies, a fully synthetic affibody, and the antibody therapeutics trastuzumab and cetuximab. The conjugates of the affibody ZHER2 and the trastuzumab antibody retained binding to their target antigens. Conjugated proteins maintain their activity in cell-based functional assays in HER2-positive BT-474 cell lines. This approach enables the rapid incorporation of carborane moieties into small molecules, peptides, and proteins for further exploration in boron neutron capture therapy, which requires the targeted delivery of boron-dense groups.
- 19 April 2022
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 144 (17) , 7852-7860
Palladium-Mediated Incorporation of Carboranes into Small Molecules, Peptides, and Proteins
Carboranes represent a class of compounds with increasing therapeutic potential. However, few general approaches to readily embed carboranes into small molecules, peptides, and proteins are available. We report a strategy based on palladium-mediated C–X (X = C, S, and N) bond formation for the installation of carborane-containing moieties onto small molecules and peptides. We demonstrate the ability of Pd-based reagents with appropriate ligands to overcome the high hydrophobicity of the carborane group and enable chemoselective conjugation of cysteine residues at room temperature in aqueous buffer. Accordingly, carboranes can be efficiently installed on proteins by employing a combination of a bis-sulfonated biarylphosphine-ligated Pd reagent in an aqueous histidine buffer. This method is successfully employed on nanobodies, a fully synthetic affibody, and the antibody therapeutics trastuzumab and cetuximab. The conjugates of the affibody ZHER2 and the trastuzumab antibody retained binding to their target antigens. Conjugated proteins maintain their activity in cell-based functional assays in HER2-positive BT-474 cell lines. This approach enables the rapid incorporation of carborane moieties into small molecules, peptides, and proteins for further exploration in boron neutron capture therapy, which requires the targeted delivery of boron-dense groups.
- 21 January 2021
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 23 (3) , 777-780
Amphiphilic Biaryl Monophosphine Ligands by Regioselective Sulfonation
Amphiphilic ligands are valued for their ability to facilitate organometallic reactions in the presence of water. The regioselective sulfonation of a series of commercially available biaryl monophosphines to generate amphiphilic ligands is presented. In this one-step protocol, the temperature and addition of fuming sulfuric acid were carefully controlled to arrive at sulfonated biaryl monophosphine ligands in high yields with >95% regioselectivity without the need for chromatographic purification.
- 21 January 2021
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 23 (3) , 777-780
Amphiphilic Biaryl Monophosphine Ligands by Regioselective Sulfonation
Amphiphilic ligands are valued for their ability to facilitate organometallic reactions in the presence of water. The regioselective sulfonation of a series of commercially available biaryl monophosphines to generate amphiphilic ligands is presented. In this one-step protocol, the temperature and addition of fuming sulfuric acid were carefully controlled to arrive at sulfonated biaryl monophosphine ligands in high yields with >95% regioselectivity without the need for chromatographic purification.
- 15 December 2020
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 142 (51) , 21237-21242
Palladium–Protein Oxidative Addition Complexes by Amine-Selective Acylation
Palladium oxidative addition complexes (OACs) are traditionally accessed by treating an aryl halide-containing substrate with a palladium(0) source. Here, a new strategy to selectively prepare stable OACs from amino groups on native proteins is presented. The approach relies on an amine-selective acylation reaction that occurs without modification of a preformed palladium(II)-aryl group. Once transferred onto a protein substrate, the palladium(II)-aryl group facilitates conjugation by undergoing reaction with a second, cysteine-containing protein. This operationally simple method is applicable to native, nonengineered enzymes as well as antibodies and is carried out in an aqueous setting and open to air. The resulting Pd–protein OACs are stable, storable reagents that retain biological activity and can be used to achieve protein–protein cross-coupling at nanomolar concentrations within hours.
- 15 December 2020
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 142 (51) , 21237-21242
Palladium–Protein Oxidative Addition Complexes by Amine-Selective Acylation
Palladium oxidative addition complexes (OACs) are traditionally accessed by treating an aryl halide-containing substrate with a palladium(0) source. Here, a new strategy to selectively prepare stable OACs from amino groups on native proteins is presented. The approach relies on an amine-selective acylation reaction that occurs without modification of a preformed palladium(II)-aryl group. Once transferred onto a protein substrate, the palladium(II)-aryl group facilitates conjugation by undergoing reaction with a second, cysteine-containing protein. This operationally simple method is applicable to native, nonengineered enzymes as well as antibodies and is carried out in an aqueous setting and open to air. The resulting Pd–protein OACs are stable, storable reagents that retain biological activity and can be used to achieve protein–protein cross-coupling at nanomolar concentrations within hours.
- 30 June 2020
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 142 (28) , 12548
Correction to “Protein–Protein Cross-Coupling via Palladium–Protein Oxidative Addition Complexes from Cysteine Residues”
- 30 June 2020
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 142 (28) , 12548
Correction to “Protein–Protein Cross-Coupling via Palladium–Protein Oxidative Addition Complexes from Cysteine Residues”
- 11 May 2020
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 142 (20) , 9124-9129
Protein–Protein Cross-Coupling via Palladium–Protein Oxidative Addition Complexes from Cysteine Residues
Few chemical methods exist for the covalent conjugation of two proteins. We report the preparation of site-specific protein-protein conjugates that arise from the sequential cross-coupling of cysteine residues on two different proteins. The method involves the synthesis of stable palladium-protein oxidative addition complexes (Pd-protein OACs), a process that converts nucleophilic cysteine residues into an electrophilic S-aryl-Pd-X unit by taking advantage of an intramolecular oxidative addition strategy. This process is demonstrated on proteins up to 83 kDa in size and can be conveniently carried out in water and open to air. The resulting Pd-protein OACs can cross-couple with other thiol-containing proteins to arrive at homogeneous protein-protein bioconjugates.
- 11 May 2020
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 142 (20) , 9124-9129
Protein–Protein Cross-Coupling via Palladium–Protein Oxidative Addition Complexes from Cysteine Residues
Few chemical methods exist for the covalent conjugation of two proteins. We report the preparation of site-specific protein-protein conjugates that arise from the sequential cross-coupling of cysteine residues on two different proteins. The method involves the synthesis of stable palladium-protein oxidative addition complexes (Pd-protein OACs), a process that converts nucleophilic cysteine residues into an electrophilic S-aryl-Pd-X unit by taking advantage of an intramolecular oxidative addition strategy. This process is demonstrated on proteins up to 83 kDa in size and can be conveniently carried out in water and open to air. The resulting Pd-protein OACs can cross-couple with other thiol-containing proteins to arrive at homogeneous protein-protein bioconjugates.
- 11 October 2017
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 139 (42) , 14901-14904
Total Syntheses of (+)- and (−)-Tetrapetalones A and C
Described herein are syntheses of the naturally occurring polyketides (-)-tetrapetalones A and C and their respective enantiomers. The employed strategy involves initial assembly of a masked N-aryl tetramic acid which is advanced via a highly selective conjugate addition/intramolecular Friedel-Crafts acylation sequence to deliver a key azepine intermediate. Application of recently developed C-H activation chemistry and subsequent Heck cyclization delivers the aglycone framework in an overall 12 steps. Resolution of the aglycone via stereospecific glycosylation with an enantiopure glycosyl donor followed by separation of the derived diastereomers enables further advancement to either (+)- or (-)-tetrapetalones A and C.
- 11 October 2017
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 139 (42) , 14901-14904
Total Syntheses of (+)- and (−)-Tetrapetalones A and C
Described herein are syntheses of the naturally occurring polyketides (-)-tetrapetalones A and C and their respective enantiomers. The employed strategy involves initial assembly of a masked N-aryl tetramic acid which is advanced via a highly selective conjugate addition/intramolecular Friedel-Crafts acylation sequence to deliver a key azepine intermediate. Application of recently developed C-H activation chemistry and subsequent Heck cyclization delivers the aglycone framework in an overall 12 steps. Resolution of the aglycone via stereospecific glycosylation with an enantiopure glycosyl donor followed by separation of the derived diastereomers enables further advancement to either (+)- or (-)-tetrapetalones A and C.
- 1 June 2016
- Published by Elsevier in Tetrahedron
- Vol. 72 (26) , 3673-3677
Synthetic studies toward tetrapetalone A: attempted palladium π-allyl cascades toward a fused tricyclic intermediate
- 1 June 2016
- Published by Elsevier in Tetrahedron
- Vol. 72 (26) , 3673-3677
Synthetic studies toward tetrapetalone A: attempted palladium π-allyl cascades toward a fused tricyclic intermediate
- 15 May 2014
- Published by Wiley
- p. 83-92
Cross‐Coupling of Alkenyl/Aryl Carboxylates with Grignard Reagents via Fe‐Catalyzed C‐O Bond Activation
- 15 May 2014
- Published by Wiley
- p. 83-92
Cross‐Coupling of Alkenyl/Aryl Carboxylates with Grignard Reagents via Fe‐Catalyzed C‐O Bond Activation